In-vitro cellular uptake and transport study of 9-nitrocamptothecin PLGA nanoparticles across caco-2 cell monolayer model

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 3, 2011, Pages 425-434

  Derakhshandeh, Katayoun ^a,b   Hochhaus, Gunther ^a   Dadashzadeh, Simin ^c  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b University of Florida   (United States)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

9 nitrocamptothecin; Caco 2 cell; Nanoparticles; Transport; Uptake

Indexed keywords

COUMARIN; RUBITECAN;

ARTICLE; CELL MEMBRANE; CELL STRAIN CACO 2; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; NANOENCAPSULATION; PRECIPITATION; SUSTAINED RELEASE FORMULATION;

EID: 84856948281     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Garcia-Carbonero R and Supko GS. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Res. (2002) 8: 641-61.
2. Gerrits CJH, Jonge MJA, Scgellens JHM, Stoter G and Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer (1997) 67: 952-62.
3. Iyer L and Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol. (1998) 42: S31-S34.
4. Stehlin JS, Giovanella BC, Natelson EA, de Ipolyi PD, Coil D, Davis B, Wolk D, Wallace P and Trojacek A. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol. (1999) 14: 821-31.
5. Fassberg J and Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. (1992) 81: 676-84.
6. Liu LF, Duann P, Ching-Tai L, D'Arpa P and Wu J. Mechanism of action of camptothecins. Ann. NY Acad. Sci. (1996) 803: 45-9.
7. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X and Danks MK. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann. NY Acad. Sci. (1996) 803: 188-201.
8. Pommier Y, Gupta M, Valenti M and Nieves-neira W. Cellular resistance to camptothecins. Ann. NY Acad. Sci. (1999) 803: 60-73.
9. Zhong DF, Li K, Xu JH, Du Y and Zhang YF. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Acta Pharmacol. Sin. (2003) 24: 256-62
10. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. (1995) 116: 1-9.
11. Labhasetwar V. Nanoparticles for drug delivery. Pharm. News (1997) 4: 28-31.
12. Moghimi SM, Hunter AC and Murray JC. Long-circulating and target specific nanoparticles: theory and practice. Pharmcol. Rev. (2001) 53: 283-318.
13. Panyam J and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. (2003) 55: 329-47.
14. Brigger I, Dubernet C and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (2002) 54: 631-51.
15. Drummond DC, Meyer O, Hoong K, Kirpotin DB and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. (1999) 51: 691-744.
16. Onishi H and Machida Y. Antitomur properties of irinotecan-containing nanoparticles prepared using poly (DL-lactic acid) and poly (ethylen glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol). Biol. Pharm. Bull. (2003) 26: 116-19.
17. Zhang L, Hu Y, Jiang X, Yang C, Lu W and Yang YH. Camptothecin derivative-loaded poly (caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their distribution in mice. J. Control. Release (2004) 96: 135-48.
18. Chen H and Lamger R. Oral particulate delivery: status and future trends. Adv. Drug Deliver. Rev. (1998) 34: 339-50.
19. Ponchel G and Irache J-M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliver. Rev. (1998) 334: 191-219.
20. Gan LS and Thakker DR. Application of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Deliver. Rev. (1997) 23: 77-98.
21. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. (1990) 79: 476-82.
22. Bvan Breemen R and Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opinion on Drug Metabolism and Toxicology (2005) 1: 175-85.
23. Gaumet M, Gurny R and Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. (2009) 36: 465-73.
24. Kolhatkar RB, Swaan P and Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm. Res. (2008) 25: 1723-9.
25. Kitchens KM, Kolhatkar RB, Swaan PW, Eddington ND and Ghandehari H. Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm. Res. (2006) 23: 2818-26.
26. Moyes SM, Smyth SH, Shipman A, Long S, Morris JF and Carr KE. Parameters influencing intestinal epithelial permeability and microparticle uptake in-vitro. Int. J. Pharm. (2007) 337: 133-41.
27. Derakhshandeh K, Erfan M and Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur. J. Pharm. Biopharm. (2007) 66: 34-41.
28. Derakhshandeh K and Dadashzadeh S. Liquid chromatography quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma. J. Chromatogr. B (2005) 818: 199-204
29. Eyles J, Alpar HO, Field WN, Lewis DA and Keswick M. The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat. J. Pharm. Pharmacol. (1995) 45: 561-65.
30. Florece AT, Hillery AM and Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target. (1995) 3: 75-80.
31. Artrsson P, Palm K and Lutheman K. Caco-2 monoayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. (1996) 22: 67-88.
32. Delie F and Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption. Advatages and limitations of the Caco-2 model. Crit. Rev. Ther. Drug Carr. Syst. (1997) 14: 221-86.
33. Kriwt B and Kissel T. Poly (acrylic acid) microparticles widen the intercellular spaces of Caco-2 cell monolayer: an examination by confocal laser scanning microscopy. Eur. J. Pharm. Biopharm. (1996) 42: 233-40.
34. Hillery AM, Toth I and Florence AT. Co-polymerised peptide particles (CPP) I: synthesis, characterization and in-vitro studies on a novel oral nanoparticulate delivery system. J. Control. Rel. (1996) 41: 271-81.
35. McClean S, Prosser E, Meehan E, O'Malle D, Clarke N and Ramtoola Z. Binding and uptake of biodegradable poly- dl- lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. (1998) 6: 153-63.
36. Manisha PD, Labhasetwar V, Walter E, Levy RJ and Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. (1997) 14: 1568-73.
37. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. (1993) 85: 271-291.
38. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. (1994) 54: 1431-1439.
39. Hertzberg RP, Caranfa MJ and Holden KG. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. (1989) 32: 715-20.
40. Wani MC, Nicholas AW, Manikumar G and Wall ME. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J. Med. Chem. (1987) 30: 1774-79.
41. Zamboni WC, Bowman LC and Tan M. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother. Pharmacol. (1999) 43: 454-58.
42. Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V and Rubin E. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). Anticancer Res. (2000) 20: 1013-16.
43. Schoemaker NE, Mathot RAA, Schoffski P, Rosing H, Schellens JHM and Beijnen JH. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemother. Pharmacol. (2002) 50: 514-17.
44. Dadashzadeh S, Derakhshandeh K and Shirazi FH. 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anticancer Drugs (2008) 19: 805-11.
45. Win KY and Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 26: 2713-22.
46. Orafai H, Kallinteri P, Garnett M, Huggins S, Hutcheon G and Pourcain C. Novel poly (glycerol-adipate) polymers used for nanoparticle making: a study of surface free energy. Iranian J. Pharm. Res. (2008) 7: 11-19.
47. Shenderova A, Bruke TG and Schewendeman SP. The acidic microclimate in poly (lactide-co-glycolide) microsopheres stabilizes camptothecins. Pharm. Res. (1999) 16: 241-48.